How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,659 results for

HIV Exposure

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Effectiveness of oral pre-exposure prophylaxis (PrEP) for HIV

. Knox DC, Anderson PL, Harrigan PR, Tan DH. Multidrug-resistant HIV-1 Infection despite preexposure prophylaxis. New England Journal of Medicine. 2017;376(5):501–2. Montgomery MC, Oldenburg CE, Nunn AS, Mena L, Anderson P, Liegler T, et al. Adherence to pre-exposure prophylaxis for HIV prevention in a clinical setting. PLoS ONE [Electronic Resource]. 2016;11(6):e0157742. Colby DJ, Kroon E, Sacdalan C, Gandhi M, Grant RM, Phanuphak P, et al. Acquisition of multidrug-resistant human immunodeficiency (...) drug-resistant mutations; the underlying cause for this infection remains unclear (15). Authors hypothesise infection with a “wild-type” HIV virus, and that frequent condomless anal sex, potential repeated exposure to HIV, repeated diagnosis of sexually transmitted infections, and the pharmacokinetics of TDF/FTC in rectal mucosa may have contributed to seroconversion (15). Practical considerations While daily oral TDF (with or without FTC) is protective against HIV infection, this is highly

2018 Ontario HIV Treatment Network

122. Prevalence and trends of markers of hepatitis B virus, hepatitis C virus and human Immunodeficiency virus in Argentine blood donors. Full Text available with Trip Pro

Prevalence and trends of markers of hepatitis B virus, hepatitis C virus and human Immunodeficiency virus in Argentine blood donors. Transfusion-transmitted infections are a major problem associated with blood transfusion. The aim of this study was to determine prevalence and trends of HBV, HCV and HIV in blood donors in Argentina.A retrospective study was carried out in blood donors of 27 transfusion centers covering the whole country over a period of eight years (2004-2011). Serologic (...) screening assays for HBsAg, anti-HBc, anti-HCV, and anti-HIV were performed in all centers and nucleic acid amplification testing (NAT) was performed in 2 out of the 27 centers.The 2,595,852 samples tested nationwide from 2004 to 2011 showed that the prevalence of HBsAg decreased from 0.336% to 0.198% (p < 0.0001), that of anti-HBc from 2.391% to 2.007% (p < 0.0001), that of anti-HCV from 0.721% to 0.460%, (p < 0.0001) and that of anti-HIV from 0.208% to 0.200 (p = 0.075). The prevalence of HBV, HCV

2014 BMC Infectious Diseases

123. A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretrov

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretrov A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected (...) With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02120352 Recruitment Status : Active, not recruiting First Posted : April 22, 2014 Last Update

2014 Clinical Trials

124. Medication Adherence in Human Immunodeficiency Virus (HIV)

Medication Adherence in Human Immunodeficiency Virus (HIV) Medication Adherence in Human Immunodeficiency Virus (HIV) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Medication Adherence in Human (...) Study Details Study Description Go to Brief Summary: Although effective treatments are currently available to treat human immunodeficiency virus (HIV), the retrovirus leading to acquired immune deficiency syndrome (AIDS), strict adherence to the treatment regimen is required. Nonadherence to highly active antiretroviral therapy (HAART) regimens is well documented in individuals with HIV. This is especially true for adolescents and young adults (AYA), where rates of adherence range from 20 to 100

2014 Clinical Trials

125. Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV)

Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02178592 Recruitment Status : Active, not recruiting

2014 Clinical Trials

126. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV

Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV UPDATED RECOMMENDATIONS ON FIRST-LINE AND SECOND-LINE ANTIRETROVIRAL REGIMENS AND POST-EXPOSURE PROPHYLAXIS AND RECOMMENDATIONS ON EARLY INFANT DIAGNOSIS OF HIV SUPPLEMENT TO THE 2016 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION DECEMBER 2018 INTERIM GUIDELINES HIV TREATMENTUPDATED (...) RECOMMENDATIONS ON FIRST-LINE AND SECOND-LINE ANTIRETROVIRAL REGIMENS AND POST-EXPOSURE PROPHYLAXIS AND RECOMMENDATIONS ON EARLY INFANT DIAGNOSIS OF HIV: INTERIM GUIDELINES SUPPLEMENT TO THE 2016 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION DECEMBER 2018WHO/CDS/HIV/18.51 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https

2019 World Health Organisation HIV Guidelines

127. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis

of initiation and dura- tion of treatment. J Virol 1998;72:4265-73. 26. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine pro- phylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-14. 27. Mayer KH, Mimiaga MJ, Gelman M, et al. Raltegravir, tenofovir DF, and emtric- itabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012;59:354-9. 28 (...) the potential for higher-quality data in humans. nPEP is not recommended for individuals who have had a low- risk exposure, regardless of source HIV status. We also do not rec- ommend nPEP for those who have had a moderate-to-high risk exposure from a source individual who is known to be HIV positive but is documented to be virologically suppressed on antiretroviral therapy, and who does not have a known concomitant STI. Of note, all PEP use is off label in Canada. We recommend beginning nPEP as soon

2017 CPG Infobase

128. Tenofovir with emtricitabine for HIV pre-exposure prophylaxis (PrEP)

option for pre-exposure prophylaxis of HIV, now widely available through general practice. 10 min read 17 July 2018 Key points Tenofovir disoproxil with emtricitabine is effective in reducing the incidence of human immunodeficiency virus (HIV) when taken as pre-exposure prophylaxis (PrEP) When compared with placebo, PrEP significantly reduced rates of HIV transmission among adults at medium to high risk of infection. In all study trials, participants also received standard prevention practices (...) This review includes a treatment adherence assessment and tests for HIV and other STIs. Evidence Snapshot What is known about this medicine combination? Tenofovir disoproxil and emtricitabine are frequently used as part of combination antiretroviral therapy for people with human immunodeficiency virus (HIV) infection. Against a background of routine risk-reduction strategies, this combination is also effective in lowering the risk of HIV infection in at-risk populations when taken as pre-exposure

2018 National Prescribing Service Limited (Australia)

129. Management of Hepatitis B Virus Infection and Prevention of Hepatitis B Virus Reactivation in Children With Acquired Immunodeficiencies or Undergoing Immune Suppressive, Cytotoxic, or Biological Modifier Therapies. Full Text available with Trip Pro

Management of Hepatitis B Virus Infection and Prevention of Hepatitis B Virus Reactivation in Children With Acquired Immunodeficiencies or Undergoing Immune Suppressive, Cytotoxic, or Biological Modifier Therapies. Reactivation of hepatitis B virus (HBV) is a known complication of immune-suppressive, cytotoxic, and biological modifier therapies in patients currently infected with HBV or who have had past exposure to HBV. Nowadays, newer and emerging forms of targeted biologic therapies

2020 Journal of Pediatric Gastroenterology and Nutrition

130. Recommendation for HIV post-exposure prophylaxis (PEP) following occupational exposure to a source with undetectable HIV viral load

Recommendation for HIV post-exposure prophylaxis (PEP) following occupational exposure to a source with undetectable HIV viral load EAGA Secretariat December 2013 Expert Advisory Group on AIDS Providing expert scientific advice on HIV Updated recommendation for HIV post-exposure prophylaxis (PEP) following occupational exposure to a source with undetectable HIV viral load At its meeting on 23 October 2013 (EAGA95), the Expert Advisory Group on AIDS (EAGA) reviewed the evidence around the risk (...) of occupational HIV transmission from a source/patient with no detectable HIV RNA in their plasma. EAGA had previously advised that HIV PEP was not recommended under these circumstances. However, guidelines published by the US Public Health Service in September 2013 recommended PEP should still be offered. Full details of the discussion at EAGA are available in the published minutes (link). The advice from EAGA is summarised below. Situation: Occupational exposure of a healthcare worker, by percutaneous

2013 Publication 4880703

131. Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study (...) Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S

2012 Clinical Trials

132. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP)

BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) Guideline writing group Michael Brady (Co-chair) Consultant in Sexual Health and HIV, King’s College Hospital, London Alison Rodger (Co-chair) Reader and Honorary Consultant Infectious Diseases and HIV, University College London David Asboe Consultant HIV and Sexual Health, Chelsea and Westminster Hospital NHS Foundation Trust, London Valentina Cambiano Lecturer in Infectious Disease Modelling and Biostatistics, University (...) on the use of HIV pre-exposure prophylaxis (PrEP) 2018 BHIVA/BASHH guidelines on the use of PrEP 2 Contents 1 Objectives 6 1.1 Inclusivity 6 2 Methods 7 2.1 Search strategy 7 2.2 GRADE system 7 2.2.1 Good practice points 8 2.3 Stakeholder involvement, piloting and feedback 8 2.4 Generic preparations of tenofovir disoproxil 8 2.5 References 8 3 Summary of recommendations 9 4 Evidence for safety and efficacy in key populations 15 4.1 Evidence for safety and efficacy in men who have sex with men (MSM) 15

2018 British Association for Sexual Health and HIV

133. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance

is underpinned by two guiding principles: promoting human rights and promoting gender equality. Source: Consolidated guideline on sexual and reproductive health and rights of women living with HIV (3).Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV 6 Fig. 1. Example of an algorithm for programmatic implementation of DTG a TLD (fixed-dose combination of TDF + 3TC + DTG) could be considered (...) Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance UPDATED RECOMMENDATIONS ON FIRST-LINE AND SECOND-LINE ANTIRETROVIRAL REGIMENS AND POST-EXPOSURE PROPHYLAXIS AND RECOMMENDATIONS ON EARLY INFANT DIAGNOSIS OF HIV JULY 2018 POLICY BRIEF HIV TREATMENT – INTERIM GUIDANCE @WHO/SEARO Gary HamptonWHO/CDS/HIV/18.18 © World Health Organization 2018 Some rights reserved

2018 World Health Organisation HIV Guidelines

134. HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies

of high-risk sexual encounters — precautions that may not be accepted by some individuals. This situation changed in 2012 with the FDA approval and availability of the fixed-dose antiviral combination emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) Truvada, manufactured by Gilead, for HIV pre-exposure prophylaxis (PrEP) in the US. Taking the antivirals once daily lowers the likelihood of HIV establishing a productive infection in the human host. 4 Clinical trials have shown this treatment (...) préexposition au virus de l'immunodéficience humaine [Internet]. Québec (QC): Ministère de la Santé et des Services sociaux; 2013. [cited 2016 Dec 9]. Available from: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014 [Internet]. Atlanta (Georgia): Centres for Disease Control; 2014. [cited 2016 Dec 20]. Available from: Commonwealth of Massachusetts. Frequently Asked Questions: Pre-exposure prophylaxis (PrEP) for HIV infection [Internet]. Boston

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

135. HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies

of high-risk sexual encounters — precautions that may not be accepted by some individuals. This situation changed in 2012 with the FDA approval and availability of the fixed-dose antiviral combination emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) Truvada, manufactured by Gilead, for HIV pre-exposure prophylaxis (PrEP) in the US. Taking the antivirals once daily lowers the likelihood of HIV establishing a productive infection in the human host. 4 Clinical trials have shown this treatment (...) préexposition au virus de l'immunodéficience humaine [Internet]. Québec (QC): Ministère de la Santé et des Services sociaux; 2013. [cited 2016 Dec 9]. Available from: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014 [Internet]. Atlanta (Georgia): Centres for Disease Control; 2014. [cited 2016 Dec 20]. Available from: Commonwealth of Massachusetts. Frequently Asked Questions: Pre-exposure prophylaxis (PrEP) for HIV infection [Internet]. Boston

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

136. Emtricitabine/Tenofovir for Post-Exposure Prophylaxis Against HIV: A Review of Clinical Effectiveness and Cost-Effectiveness

Emtricitabine/Tenofovir for Post-Exposure Prophylaxis Against HIV: A Review of Clinical Effectiveness and Cost-Effectiveness Emtricitabine/Tenofovir for Post-Exposure Prophylaxis Against HIV: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Emtricitabine/Tenofovir for Post-Exposure Prophylaxis Against HIV: A Review of Clinical Effectiveness and Cost-Effectiveness Emtricitabine/Tenofovir for Post-Exposure Prophylaxis Against HIV: A Review (...) of Clinical Effectiveness and Cost-Effectiveness Published on: March 17, 2017 Project Number: RC0868-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of emtricitabine/tenofovir, with or without integrase strand transfer inhibitors, compared with alternative antiretroviral drug regimens for post-exposure prophylaxis against HIV? What is the cost-effectiveness of emtricitabine/tenofovir, with or without

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

137. Correction: A randomised controlled trial of a telephone administered brief HIV risk reduction intervention amongst men who have sex with men prescribed post-exposure prophylaxis for HIV after sexual exposure in the UK: Project PEPSE. Full Text available with Trip Pro

Correction: A randomised controlled trial of a telephone administered brief HIV risk reduction intervention amongst men who have sex with men prescribed post-exposure prophylaxis for HIV after sexual exposure in the UK: Project PEPSE. [This corrects the article DOI: 10.1371/journal.pone.0216855.].

2019 PloS one Controlled trial quality: uncertain

138. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Full Text available with Trip Pro

Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. This report updates US Public Health Service recommendations for the management of healthcare personnel (HCP) who experience occupational exposure to blood and/or other body fluids that might contain human immunodeficiency virus (HIV). Although the principles of exposure management remain unchanged, recommended HIV (...) postexposure prophylaxis (PEP) regimens and the duration of HIV follow-up testing for exposed personnel have been updated. This report emphasizes the importance of primary prevention strategies, the prompt reporting and management of occupational exposures, adherence to recommended HIV PEP regimens when indicated for an exposure, expert consultation in management of exposures, follow-up of exposed HCP to improve adherence to PEP, and careful monitoring for adverse events related to treatment, as well

2013 Infection control and hospital epidemiology

139. A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting (...) registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) The safety and scientific validity of this study is the responsibility of the study sponsor

2013 Clinical Trials

140. Vitamin D status of human immunodeficiency virus-positive patients with advanced liver disease enrolled in the solid organ transplantation in HIV: Multi-site study. Full Text available with Trip Pro

Vitamin D status of human immunodeficiency virus-positive patients with advanced liver disease enrolled in the solid organ transplantation in HIV: Multi-site study. An optimal vitamin D status may benefit liver transplantation (LT) patients. Higher levels of 25-hydroxyvitamin D [25(OH)D] mitigate steroid-induced bone loss after LT, correlate with better hepatitis C virus treatment responses, and increase graft survival. This study investigated 25(OH)D levels and assessed strategies for vitamin (...) D deficiency prevention in human immunodeficiency virus (HIV)-positive patients with advanced liver disease who were enrolled in the Solid Organ Transplantation in HIV: Multi-Site Study. 25(OH)D was measured in banked specimens from 154 LT candidates/recipients with the DiaSorin assay; deficiency was defined as a 25(OH)D level < 20 ng/mL. Information about vitamin D supplement use after LT was obtained from medication logs and via surveys. Logistic regression, Cox regression, and linear repeated

2013 Liver Transplantation

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>